MAXCYTE, INC.

MXCT
About the company

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Country: United StatesPrice: $1.19Market Cap: $122.9M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

3 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 10 investors flag at least one cash flow criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2611 (Top 84.3%)FAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILNEUTRALNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-25

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-42.1M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-21.4M
      ✗LynchPositive and growing
      Operating Cash Flow$-34.4M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-16.99%, ROA=-22.04%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-29.4%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/7 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-16.9%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/7 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-21.4M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-17.46%; #3467/4519 (top 76.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 1✗ 12▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -3.0% vs Rev: -0.1%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-0.23 (2019) -> $-0.42 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/7 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-6.7%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency0/5 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 88.5% -> 81.2%, operating margin -117.0% -> -157.1%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR4.8%
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts0% pass✗ 14▾

      Split decision: 13 FAIL · 3 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #2611✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✗AckmanFAIL (1/9)✗TempletonFAIL (2/8)✗SleepFAIL (1/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)•SchlossNEUTRAL (4/7)•OshaughnessyNEUTRAL (Not ranked)
    • Profitability6% pass✓ 2✗ 33▾

      15 of 16 flag MXCT's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/8 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/8 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-15.8%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-157.1% (latest)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-42.1M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-18.5%
      ✗Lynch> 15%
      EBIT / Enterprise Value-50.5%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-50.5%, ROC=-51.1%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-22.04%
      ✗PiotroskiROA > 0
      ROA Change YoY-17.14% -> -22.04% (delta: -4.89%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-16.99%, ROA=-22.04%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY81.6% -> 81.2%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-81.4%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-18.5%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.7x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-20.8% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/7 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-98.0%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-18.5%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-117.0% (2023) -> -157.1% (2025)
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 88.5% -> 81.2%, operating margin -117.0% -> -157.1%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-22.77%; #4635/6340 (top 73.1%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+15.25%; #2414/3702 (top 65.2%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-18.54%; #3652/5226 (top 69.9%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.0566; #2732/5884 (top 46.4%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/7 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag MXCT's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities7.83
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDA
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Valuation8% pass✓ 8✗ 20▾

      12 of 13 flag MXCT's valuation — Graham, Lynch, Greenblatt +9 more

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.7x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-50.5%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-50.5%, ROC=-51.1%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share0.7x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-33.1%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-29.4%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.7x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low169% of trailing low ($0.70)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-22.77%; #4635/6340 (top 73.1%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+1.2284; #1170/6449 (top 18.1%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share0.74x
      ✓SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change+273.8%
      ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.2798; #3415/5247 (top 65.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-17.46%; #3467/4519 (top 76.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+50.37%; #646/6202 (top 10.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag MXCT's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio7.83
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)-20.1%
      ✗Buffett> 10%
      ROIC - WACC-30.1%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-51.1%
      ✗Greenblatt> 25%
      Current Ratio Change YoY10.88 -> 8.30
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.16x -> 0.16x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities7.83
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/2 years above 12% (latest -8.5%)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Business Services
    SIC Sector: Engineering & Management Services
    Size: Micro Cap($122.9M)
    Revenue: $33.0M-14.5% YoY
    Net Income: $44.6M-8.7% YoY

    Financial Snapshot

    Operating Margin-157.1%
    Return on Equity-26.0%
    Debt / Equity--
    Current Ratio8.30
    EPS (Diluted)$-0.42
    Shares Retired−0.8% / −2.6% 2y

    Shareholder Return

    Fiscal 2025

    Issued 0.8% of shares last year, 2.6% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, depreciation amortization, capex, buybacks.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex, buybacks.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-25
    FY 2024
    Sources
    • 10-K · 2025-03-11
    FY 2023
    Sources
    • 10-K · 2024-03-12
    FY 2022
    Sources
    • 10-K · 2023-03-15
    FY 2021
    Sources
    • 10-K · 2022-03-22
    Market Cap$122.9Mcurrent------$96.9Mest.$478.2Mest.$530.0Mest.$601.0Mest.$655.7Mest.
    Revenue$34.4M$10.2M↑49%$7.3M↓15%$9.7M↓7%$33.0M↓15%$38.6M↓6%$41.3M↓7%$44.3M↑31%$33.9M
    Operating Income-$33.7M↑37%-$6.0M↑57%-$10.2M↑28%-$6.2M↑50%-$51.9M↓1%-$51.2M↓6%-$48.3M↓77%-$27.4M↓50%-$18.2M
    Net Income-$28.0M↑39%-$4.8M↑62%-$8.9M↑28%-$4.8M↑54%-$44.6M↓9%-$41.1M↓8%-$37.9M↓61%-$23.6M↓24%-$19.1M
    EPS (Diluted)--$-0.05↑58%$-0.08↑33%$-0.04$-0.42↓8%$-0.39↓5%$-0.37↓61%$-0.23↓10%$-0.21
    Gross Margin81.0%↑1%83.4%↑9%77.0%↓6%83.7%↓2%81.2%↓1%81.6%↓8%88.5%88.5%↓1%89.2%
    Operating Margin-98.0%↑37%-59.5%↑71%-140.7%↑16%-64.1%↑46%-157.1%↓19%-132.5%↓13%-117.0%↓89%-61.8%↓15%-53.7%
    ROE-18.5%↑27%———-26.0%↓31%-19.9%↓22%-16.3%↓76%-9.3%↓28%-7.3%
    Total Debt------$0------$0$0
    Shareholders' Equity$150.9M↓16%$150.9M↓16%$158.8M↓17%$167.9M↓16%$171.5M↓17%$206.3M↓11%$232.2M↓9%$254.0M↓3%$262.9M
    Current Ratio7.83↑1%7.83↑1%12.26↓1%12.04↓2%8.30↓24%10.88↑2%10.65↓35%16.35↓6%17.32
    Debt / Equity———0.00———0.000.00
    Operating Cash Flow-$21.0M↑47%-$5.5M↑26%-$4.7M↑53%-$8.2M↑43%-$34.4M↓25%-$27.6M↓27%-$21.7M↓47%-$14.8M↓38%-$10.7M
    Free Cash Flow-$21.4M↑48%-$5.6M↑28%-$4.7M↑55%-$8.2M↑45%-$36.2M↓24%-$29.3M↓15%-$25.4M↑24%-$33.3M↓129%-$14.5M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Business Services

    MXCT vs Peers — Financial Grading

    Revenue$33.0MBottom 25%
    Net Income$44.6MMedian
    ROE-26.0%Bottom 25%
    D/E—
    Op. Margin-157.1%Bottom 25%
    Curr. Ratio8.30Top 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    AUTOMATIC DATA PROCESSING INCADP$122.3B$309.93$21.9B$4.4B73.2%0.8224.2%1.054/95/93/70/3F-Score 65/11
    ELECTRONIC ARTS INC.EA$52.9B$209.70$7.5B$887.0M13.1%0.2215.4%1.051/94/94/70/3F-Score 66/11
    Rubrik, Inc.RBRK$22.6B$109.88$1.3B$348.8M67.1%—-26.2%1.691/90/92/70/3F-Score 62/11
    AECOMACM$9.1B$70.50$16.1B$561.8M22.5%1.096.4%1.141/93/93/71/3F-Score 82/11
    COMMVAULT SYSTEMS INCCVLT$6.2B$152.07$1.2B$70.7M942.8%—6.3%1.951/92/94/70/3F-Score 66/11
    WPP plcWPP$6.0B$27.79$18.2B$289.5M-8.5%1.942.8%0.891/92/91/70/3F-Score 32/11
    VARONIS SYSTEMS INCVRNS$5.6B$48.94$623.5M$129.3M-21.6%0.76-23.5%1.971/90/91/70/3F-Score 51/11
    ROBERT HALF INC.RHI$4.3B$42.00$5.4B$133.0M10.4%—1.4%1.532/95/91/70/3F-Score 52/11